171 related articles for article (PubMed ID: 18985812)
1. Sildenafil does not influence hepatic venous pressure gradient in patients with cirrhosis.
Clemmesen JO; Giraldi A; Ott P; Dalhoff K; Hansen BA; Larsen FS
World J Gastroenterol; 2008 Oct; 14(40):6208-12. PubMed ID: 18985812
[TBL] [Abstract][Full Text] [Related]
2. Sildenafil has no effect on portal pressure but lowers arterial pressure in patients with compensated cirrhosis.
Tandon P; Inayat I; Tal M; Spector M; Shea M; Groszmann RJ; Garcia-Tsao G
Clin Gastroenterol Hepatol; 2010 Jun; 8(6):546-9. PubMed ID: 20144739
[TBL] [Abstract][Full Text] [Related]
3. Clinical use of sildenafil in pulmonary artery hypertension.
Singh TP
Expert Rev Respir Med; 2010 Feb; 4(1):13-9. PubMed ID: 20387288
[TBL] [Abstract][Full Text] [Related]
4. Sildenafil therapy for pulmonary hypertension before and after pediatric congenital heart surgery.
Palma G; Giordano R; Russolillo V; Cioffi S; Palumbo S; Mucerino M; Poli V; Vosa C
Tex Heart Inst J; 2011; 38(3):238-42. PubMed ID: 21720460
[TBL] [Abstract][Full Text] [Related]
5. Safety, tolerability and pharmacokinetics of an intravenous bolus of sildenafil in patients with pulmonary arterial hypertension.
Vachiery JL; Huez S; Gillies H; Layton G; Hayashi N; Gao X; Naeije R
Br J Clin Pharmacol; 2011 Feb; 71(2):289-92. PubMed ID: 21219411
[TBL] [Abstract][Full Text] [Related]
6. Systemic and splanchnic haemodynamic effects of sildenafil in an in vivo animal model of cirrhosis support for a risk in cirrhotic patients.
Colle I; De Vriese AS; Van Vlierberghe H; Lameire NH; DeVos M
Liver Int; 2004 Feb; 24(1):63-8. PubMed ID: 15102002
[TBL] [Abstract][Full Text] [Related]
7. Sildenafil in the treatment of pulmonary hypertension.
Barnett CF; Machado RF
Vasc Health Risk Manag; 2006; 2(4):411-22. PubMed ID: 17323595
[TBL] [Abstract][Full Text] [Related]
8. Effect of vardenafil, an inhibitor of phosphodiesterase-5, on portal haemodynamics in normal and cirrhotic liver -- results of a pilot study.
Deibert P; Schumacher YO; Ruecker G; Opitz OG; Blum HE; Rössle M; Kreisel W
Aliment Pharmacol Ther; 2006 Jan; 23(1):121-8. PubMed ID: 16393289
[TBL] [Abstract][Full Text] [Related]
9. Sildenafil decreased pulmonary arterial pressure but may have exacerbated portal hypertension in a patient with cirrhosis and portopulmonary hypertension.
Wang YW; Lin HC; Yang YY; Hou MC; Lee SD
J Gastroenterol; 2006 Jun; 41(6):593-7. PubMed ID: 16868809
[TBL] [Abstract][Full Text] [Related]
10. Effects of isosorbide-5-mononitrate on variceal pressure and systemic and splanchnic haemodynamics in patients with cirrhosis.
Escorsell A; Feu F; Bordas JM; García-Pagán JC; Luca A; Bosch J; Rodés J
J Hepatol; 1996 Apr; 24(4):423-9. PubMed ID: 8738728
[TBL] [Abstract][Full Text] [Related]
11. The use of sildenafil to treat portopulmonary hypertension prior to liver transplantation.
Cadden IS; Greanya ED; Erb SR; Scudamore CH; Yoshida EM
Ann Hepatol; 2009; 8(2):158-61. PubMed ID: 19502663
[TBL] [Abstract][Full Text] [Related]
12. A randomized study of losartan vs propranolol: Effects on hepatic and systemic hemodynamics in cirrhotic patients.
Castaño G; Viudez P; Riccitelli M; Sookoian S
Ann Hepatol; 2003; 2(1):36-40. PubMed ID: 15094704
[TBL] [Abstract][Full Text] [Related]
13. Sildenafil improves skeletal muscle oxygenation during exercise in men with intermittent claudication.
Roseguini BT; Hirai DM; Alencar MC; Ramos RP; Silva BM; Wolosker N; Neder JA; Nery LE
Am J Physiol Regul Integr Comp Physiol; 2014 Aug; 307(4):R396-404. PubMed ID: 24944249
[TBL] [Abstract][Full Text] [Related]
14. Perioperative sildenafil therapy for pulmonary hypertension in infants undergoing congenital cardiac defect closure.
El Midany AA; Mostafa EA; Azab S; Hassan GA
Interact Cardiovasc Thorac Surg; 2013 Dec; 17(6):963-8. PubMed ID: 23985411
[TBL] [Abstract][Full Text] [Related]
15. Influence of somatostatin on splanchnic haemodynamics in patients with liver cirrhosis.
Eriksson LS; Law DH; Sato Y; Wahren J
Clin Physiol; 1984 Feb; 4(1):5-11. PubMed ID: 6141861
[TBL] [Abstract][Full Text] [Related]
16. Effects of nifedipine on hepatic venous pressure gradient and portal vein blood flow in patients with cirrhosis.
Ota K; Shijo H; Kokawa H; Kubara K; Kim T; Akiyoshi N; Yokoyama M; Okumura M
J Gastroenterol Hepatol; 1995; 10(2):198-204. PubMed ID: 7787167
[TBL] [Abstract][Full Text] [Related]
17. Dramatic beneficial effects of sildenafil in recurrent massive pulmonary embolism.
Ganière V; Feihl F; Tagan D
Intensive Care Med; 2006 Mar; 32(3):452-4. PubMed ID: 16450094
[TBL] [Abstract][Full Text] [Related]
18. Damping index of Doppler hepatic vein waveform to assess the severity of portal hypertension and response to propranolol in liver cirrhosis: a prospective nonrandomized study.
Kim MY; Baik SK; Park DH; Lim DW; Kim JW; Kim HS; Kwon SO; Kim YJ; Chang SJ; Lee SS
Liver Int; 2007 Oct; 27(8):1103-10. PubMed ID: 17845539
[TBL] [Abstract][Full Text] [Related]
19. Hemodynamics and pharmacokinetics of tezosentan, a dual endothelin receptor antagonist, in patients with cirrhosis.
Lebrec D; Bosch J; Jalan R; Dudley FJ; Jessic R; Moreau R; Garcia-Pagan JC; Mookerjee RP; Chiossi E; Van Giersbergen PL; Kusic-Pajic A; Dingemanse J
Eur J Clin Pharmacol; 2012 May; 68(5):533-41. PubMed ID: 22101624
[TBL] [Abstract][Full Text] [Related]
20. Clinical potential of combined organic nitrate and phosphodiesterase type 5 inhibitor in treatment-resistant hypertension.
Oliver JJ; Hughes VE; Dear JW; Webb DJ
Hypertension; 2010 Jul; 56(1):62-7. PubMed ID: 20479335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
